Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma

Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are increased, with some degree of overlap with other phenotypes. Systematic reviews assessed the efficacy and safety of benralizumab, dupilumab and omalizumab (alphabetical order) vs standard of care for patients with unc...

ver descrição completa

Detalhes bibliográficos
Autores: Agache, I, Rocha, C, Beltran, J, Song, Y, Posso, M, Sola, I, Alonso-Coello, P, Akdis, C, Akdis, M, Canonica, GW, Casale, T, Chivato, T, Corren, J, Del Giacco, S, Eiwegger, T, Firinu, D, Gern, JE, Hamelmann, E, Hanania, N, Makela, M, Martin, IH, Nair, P, O'Mahony, L, Papadopoulos, NG, Papi, A, Park, HS, de Llano, LP, Quirce, S, Sastre, J, Shamji, M, Schwarze, J, Canelo-Aybar, C, Palomares, O, Jutel, M
Formato: artículo
Estado:Versión publicada
Fecha de publicación:2020
País:España
Recursos:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
Repositorio:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
OAI Identifier:oai:iibsantpau.fundanetsuite.com:p1722
Acesso em linha:https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1722
https://hdl.handle.net/11584/295340
Access Level:acceso abierto
Palavra-chave:benralizumab
dupilumab
exacerbations
omalizumab
severe allergic asthma
id ES_55eb048eaccaf824d3e73cd96fd07082
oai_identifier_str oai:iibsantpau.fundanetsuite.com:p1722
network_acronym_str ES
network_name_str España
repository_id_str
spelling Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthmaAgache, IRocha, CBeltran, JSong, YPosso, MSola, IAlonso-Coello, PAkdis, CAkdis, MCanonica, GWCasale, TChivato, TCorren, JDel Giacco, SEiwegger, TFirinu, DGern, JEHamelmann, EHanania, NMakela, MMartin, IHNair, PO'Mahony, LPapadopoulos, NGPapi, APark, HSde Llano, LPQuirce, SSastre, JShamji, MSchwarze, JCanelo-Aybar, CPalomares, OJutel, Mbenralizumabdupilumabexacerbationsomalizumabsevere allergic asthmaAllergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are increased, with some degree of overlap with other phenotypes. Systematic reviews assessed the efficacy and safety of benralizumab, dupilumab and omalizumab (alphabetical order) vs standard of care for patients with uncontrolled severe allergic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma-related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE. All three biologicals reduced with high certainty the annualized asthma exacerbation rate: benralizumab incidence rate ratios (IRR) 0.63 (95% CI 0.50 - 0.81); dupilumab IRR 0.58 (95%CI 0.47 - 0.73); and omalizumab IRR 0.56 (95%CI 0.42 - 0.73). Benralizumab and dupilumab improved asthma control with high certainty and omalizumab with moderate certainty; however, none reached the minimal important difference (MID). Both benralizumab and omalizumab improved QoL with high certainty, but only omalizumab reached the MID. Omalizumab enabled ICS dose reduction with high certainty. Benralizumab and omalizumab showed an increase in drug-related adverse events (AEs) with low to moderate certainty. All three biologicals had moderate certainty for an ICER/QALY value above the willingness to pay threshold. There was high certainty that in children 6-12 years old omalizumab decreased the annualized exacerbation rate [IRR 0.57 (95%CI 0.45-0.72)], improved QoL [relative risk 1.43 (95%CI 1.12 -1.83)], reduced ICS [mean difference (MD) -0.45 (95% CI -0.58 to -0.32)] and rescue medication use [ MD -0.41 (95%CI -0.66 to -0.15)].WILEY2020info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionhttps://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1722https://hdl.handle.net/11584/295340ALLERGYISSN: 01054538ISSNe: 13989995reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pauinstname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)Inglésinfo:eu-repo/semantics/openAccessoai:iibsantpau.fundanetsuite.com:p17222026-06-14T12:41:47Z
dc.title.none.fl_str_mv Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
title Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
spellingShingle Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
Agache, I
benralizumab
dupilumab
exacerbations
omalizumab
severe allergic asthma
title_short Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
title_full Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
title_fullStr Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
title_full_unstemmed Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
title_sort Efficacy and safety of treatment with biologicals (benralizumab, dupilumab and omalizumab) for severe allergic asthma: A systematic review for the EAACI Guidelines - recommendations on the use of biologicals in severe asthma
dc.creator.none.fl_str_mv Agache, I
Rocha, C
Beltran, J
Song, Y
Posso, M
Sola, I
Alonso-Coello, P
Akdis, C
Akdis, M
Canonica, GW
Casale, T
Chivato, T
Corren, J
Del Giacco, S
Eiwegger, T
Firinu, D
Gern, JE
Hamelmann, E
Hanania, N
Makela, M
Martin, IH
Nair, P
O'Mahony, L
Papadopoulos, NG
Papi, A
Park, HS
de Llano, LP
Quirce, S
Sastre, J
Shamji, M
Schwarze, J
Canelo-Aybar, C
Palomares, O
Jutel, M
author Agache, I
author_facet Agache, I
Rocha, C
Beltran, J
Song, Y
Posso, M
Sola, I
Alonso-Coello, P
Akdis, C
Akdis, M
Canonica, GW
Casale, T
Chivato, T
Corren, J
Del Giacco, S
Eiwegger, T
Firinu, D
Gern, JE
Hamelmann, E
Hanania, N
Makela, M
Martin, IH
Nair, P
O'Mahony, L
Papadopoulos, NG
Papi, A
Park, HS
de Llano, LP
Quirce, S
Sastre, J
Shamji, M
Schwarze, J
Canelo-Aybar, C
Palomares, O
Jutel, M
author_role author
author2 Rocha, C
Beltran, J
Song, Y
Posso, M
Sola, I
Alonso-Coello, P
Akdis, C
Akdis, M
Canonica, GW
Casale, T
Chivato, T
Corren, J
Del Giacco, S
Eiwegger, T
Firinu, D
Gern, JE
Hamelmann, E
Hanania, N
Makela, M
Martin, IH
Nair, P
O'Mahony, L
Papadopoulos, NG
Papi, A
Park, HS
de Llano, LP
Quirce, S
Sastre, J
Shamji, M
Schwarze, J
Canelo-Aybar, C
Palomares, O
Jutel, M
author2_role author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
author
dc.subject.none.fl_str_mv benralizumab
dupilumab
exacerbations
omalizumab
severe allergic asthma
topic benralizumab
dupilumab
exacerbations
omalizumab
severe allergic asthma
description Allergic asthma is a frequent asthma phenotype. Both IgE and type 2 cytokines are increased, with some degree of overlap with other phenotypes. Systematic reviews assessed the efficacy and safety of benralizumab, dupilumab and omalizumab (alphabetical order) vs standard of care for patients with uncontrolled severe allergic asthma. PubMed, Embase and Cochrane Library were searched to identify RCTs and health economic evaluations, published in English. Critical and important asthma-related outcomes were evaluated. The risk of bias and the certainty of the evidence were assessed using GRADE. All three biologicals reduced with high certainty the annualized asthma exacerbation rate: benralizumab incidence rate ratios (IRR) 0.63 (95% CI 0.50 - 0.81); dupilumab IRR 0.58 (95%CI 0.47 - 0.73); and omalizumab IRR 0.56 (95%CI 0.42 - 0.73). Benralizumab and dupilumab improved asthma control with high certainty and omalizumab with moderate certainty; however, none reached the minimal important difference (MID). Both benralizumab and omalizumab improved QoL with high certainty, but only omalizumab reached the MID. Omalizumab enabled ICS dose reduction with high certainty. Benralizumab and omalizumab showed an increase in drug-related adverse events (AEs) with low to moderate certainty. All three biologicals had moderate certainty for an ICER/QALY value above the willingness to pay threshold. There was high certainty that in children 6-12 years old omalizumab decreased the annualized exacerbation rate [IRR 0.57 (95%CI 0.45-0.72)], improved QoL [relative risk 1.43 (95%CI 1.12 -1.83)], reduced ICS [mean difference (MD) -0.45 (95% CI -0.58 to -0.32)] and rescue medication use [ MD -0.41 (95%CI -0.66 to -0.15)].
publishDate 2020
dc.date.none.fl_str_mv 2020
dc.type.none.fl_str_mv info:eu-repo/semantics/article
info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.none.fl_str_mv https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1722
https://hdl.handle.net/11584/295340
url https://iibsantpau.fundanetsuite.com/Publicaciones/ProdCientif/PublicacionFrw.aspx?id=1722
https://hdl.handle.net/11584/295340
dc.language.none.fl_str_mv Inglés
language_invalid_str_mv Inglés
dc.rights.none.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.publisher.none.fl_str_mv WILEY
publisher.none.fl_str_mv WILEY
dc.source.none.fl_str_mv ALLERGY
ISSN: 01054538
ISSNe: 13989995
reponame:r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
instname:Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
instname_str Institut d’Investigació Biomèdica Sant Pau (IIB Sant Pau)
reponame_str r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
collection r-IIB SANT PAU. Repositorio Institucional de Producción Científica del Instituto de Investigación Biomédica Sant Pau
repository.name.fl_str_mv
repository.mail.fl_str_mv
_version_ 1869408341951774720
score 15.812429

Registos relacionados